TRASTUZUMAB AND PERTUZUMAB COMBINATION THERAPY ACTIVATES COMPLEMENT-DEPENDENT CYTOTOXICITY AND PHAGOCYTOSIS AGAINST HER2+BREAST CANCER

被引：0
|
作者：
Tsao, Li-Chung [1 ]
Hartman, Zachary [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
617
引用
收藏
页码：A647 / A647
页数：1
相关论文
共 50 条
  • [21] First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
    Araki, Kazuhiro
    Fukada, Ippei
    Yanagi, Hiroyo
    Kobayashi, Kokoro
    Shibayama, Tomoko
    Horii, Rie
    Takahashi, Shunji
    Akiyama, Futoshi
    Ohno, Shinji
    Ito, Yoshinori
    BREAST, 2017, 35 : 78 - 84
  • [22] THE CHALLENGE OF VALUE-BASED PRICING IN COMBINATION THERAPY:THE CASE OF TRASTUZUMAB AND PERTUZUMAB IN HER2+METASTATIC BREAST CANCER
    Jiao, B.
    Garrison, L. P.
    VALUE IN HEALTH, 2020, 23 : S34 - S35
  • [23] The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+metastatic breast cancer
    Jiao, Boshen
    Garrison, Louis P., Jr.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 495 - 502
  • [24] Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+Breast Cancer (ADEPT trial)
    Waks, Adrienne G.
    Chen, Emily L.
    Graham, Noah
    Frey, Anna Mae
    Almeida, Kenneth
    Attaya, Victoria
    Ryding, Cari
    Abbass, Ibrahim
    Fung, Anita
    Sussell, Jesse
    Cortazar, Patricia
    Harvey, Caroline
    Leth, Denise
    Faggen, Meredith
    Sinclair, Natalie
    Walsh, Jeanna
    Tung, Nadine
    Sinclair, Sarah
    Lo, Steve
    Yardley, Denise
    Valero, Vicente
    Meisel, Jane
    Ballinger, Tarah J.
    Adams, Sylvia
    Carey, Lisa A.
    Rauch, Julia K.
    Abramson, Vandana G.
    Williams, Nicole O.
    Chen, Wendy Y.
    Leone, Jose P.
    Schumer, Susan T.
    Tayob, Nabihah
    Tolaney, Sara M.
    JCO ONCOLOGY PRACTICE, 2025, 21 (03)
  • [25] Incidence of hypomagnesemia in patients with HER2+breast cancer treated with pertuzumab.
    Shah, Nirja
    Daily, Karen Colleen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Sonodynamic Therapy for HER2+Breast Cancer with Iodinated Heptamethine Cyanine-Trastuzumab Conjugate
    Kobzev, Dmytro
    Semenova, Olga
    Aviel-Ronen, Sarit
    Kulyk, Olesia
    Carmieli, Raanan
    Mirzabekov, Tajib
    Gellerman, Gary
    Patsenker, Leonid
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (18)
  • [27] CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity
    Wang, Yu
    Yang, Ya-Jun
    Wang, Zhu
    Liao, Juan
    Liu, Mei
    Zhong, Xiao-Rong
    Zheng, Hong
    Wang, Yan-Ping
    ONCOLOGY LETTERS, 2017, 14 (03) : 2961 - 2969
  • [28] Physician perceptions to use of trastuzumab in HER2+breast cancer in India
    Ramanjinappa, N.
    Agarwal, J.
    Upveja, K. H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1437 - S1437
  • [29] Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+breast cancer: a plain language summary of the PHERGain study
    Perez-Garcia, Jose Manuel
    Gebhart, Geraldine
    Borrego, Manuel Ruiz
    Schmid, Peter
    Marme, Frederik
    Prat, Aleix
    Dalenc, Florence
    Kerrou, Khaldoun
    Colleoni, Marco
    Braga, Sofia
    Malfettone, Andrea
    Sampayo-Cordero, Miguel
    Cortes, Javier
    Llombart-Cussac, Antonio
    FUTURE ONCOLOGY, 2022, 18 (33) : 3677 - 3688
  • [30] Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
    Irelli, Azzurra
    Ceriello, Laura
    Patruno, Leonardo Valerio
    Tessitore, Alessandra
    Alesse, Edoardo
    Cannita, Katia
    Fabiani, Donatello
    BIOMEDICINES, 2024, 12 (01)
12345